Bausch + Lomb announced the presentation of one podium and two poster presentations at the World Cornea Congress VIII meeting, which will take place in Chicago from Sept. 28-29, 2022.
The podium presentation will feature findings from the pivotal Phase 3 trials of the investigational treatment NOV03 (perfluorohexyloctane), and the poster presentations will include pre-clinical data of NOV03 and data from Bausch + Lomb’s ongoing Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study. The ARMOR study is the only ongoing surveillance study of its kind that evaluates profiles and trends in antibiotic resistance among common ocular bacterial pathogens across the United States.
“With the recent FDA acceptance of the New Drug Application for NOV03, we look forward to attending the World Cornea Congress so we can share valuable insights from our NOV03 clinical development program with the ophthalmic community,” said Christina Ackermann, president, Ophthalmic Pharmaceuticals, Bausch + Lomb. “We will also present findings from our unique ARMOR study, which for more than a decade has helped guide eye care professionals in selecting the most appropriate antibiotic treatment options to meet the needs of their patients.”
Following is a complete list of titles and lead authors for each of the presentations:
- “NOV03 for the Treatment of Signs and Symptoms of Dry Eye Disease Associated with Meibomian Gland Dysfunction: GOBI and MOJAVE Study Findings.” Tauber et al.
- “In Vitro Antibiotic Resistance among Bacterial Pathogens Sourced from the Cornea in ARMOR.” Asbell et al.
- “In Vitro Studies of Perfluorohexyloctane, an Investigational Eye Drop for Dry Eye Disease.” Borchman et al.
Click HERE for the press release.